IOVANCE BIOTHERAPEUTICS INC
NASDAQ: IOVA (Iovance Biotherapeutics, Inc.)
Kemas kini terakhir: semalam, 5:53AM2.45
-0.16 (-6.13%)
| Penutupan Terdahulu | 2.61 |
| Buka | 2.65 |
| Jumlah Dagangan | 9,584,198 |
| Purata Dagangan (3B) | 14,463,640 |
| Modal Pasaran | 972,571,520 |
| Harga / Jualan (P/S) | 3.37 |
| Harga / Buku (P/B) | 1.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -176.49% |
| Margin Operasi (TTM) | -245.76% |
| EPS Cair (TTM) | -1.22 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6,798.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.00% |
| Nisbah Semasa (MRQ) | 4.18 |
| Aliran Tunai Operasi (OCF TTM) | -334.39 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -184.76 M |
| Pulangan Atas Aset (ROA TTM) | -27.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.85% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Iovance Biotherapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 0.5 |
| Purata | 1.88 |
|
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.37% |
| % Dimiliki oleh Institusi | 81.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mhr Fund Management Llc | 30 Sep 2025 | 28,967,103 |
| Invenomic Capital Management Lp | 30 Sep 2025 | 10,541,608 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 17.00 (Chardan Capital, 593.88%) | Beli |
| Median | 10.00 (308.16%) | |
| Rendah | 9.00 (HC Wainwright & Co., 267.35%) | Beli |
| Purata | 12.00 (389.80%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 2.28 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 17 Dec 2025 | 10.00 (308.16%) | Beli | 2.52 |
| 24 Nov 2025 | 9.00 (267.35%) | Beli | 2.50 | |
| Chardan Capital | 06 Nov 2025 | 17.00 (593.88%) | Beli | 2.31 |
| HC Wainwright & Co. | 29 Oct 2025 | 9.00 (267.35%) | Beli | 2.00 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Dec 2025 | Pengumuman | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 21 Nov 2025 | Pengumuman | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 06 Nov 2025 | Pengumuman | Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results |
| 03 Nov 2025 | Pengumuman | Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) |
| 23 Oct 2025 | Pengumuman | Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 |
| 17 Oct 2025 | Pengumuman | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 15 Oct 2025 | Pengumuman | Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |